Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 351

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 351
---
 shares (basic and diluted) |     |              | 1,048,632 |   |     |              | 4,193,689 |   |     |             | 39,385,272 |   |
| Weighted average loss per share (basic and diluted)     |     | $            |     (1.94 | ) |     | $            |     (0.03 | ) |     | $           |      (0.16 | ) |

____________ (1)Book value per share is calculated using the formula: total shareholders’ equity from the balance sheet as of December 31, 2024 divided by shares outstanding as of December 31, 2024. (2)The pro forma combined numbers include the adjustments according to Kadimastem’s and NLS’s Unaudited Pro Forma Condensed Combined Balance Sheets as presented in this proxy statement/prospectus on page 269.

165 NLS BUSINESS History and Development of the Company NLS was incorporated on June10, 2015, as a Swiss limited company. In 2016, NLS acquired several patents from Assistance Publique — Hopitaux de Paris, or AP -HP, in France, including for NLS’s lead compound mazindol. Since the founding of NLS, NLS has assembled an experienced leadership team with a track record of developing and repurposing products to treat rare neurological disorders. NLS’s Chief Executive Officer, Alexander Zwyer, has held a variety of senior leadership roles of increasing responsibility in the pharmaceutical industry, including global roles in business development, sales and marketing, medical as well as regulatory affairs, and general management. NLS complements its management team with a group of scientific and clinical advisors that includes internationally recognized North American and European experts in CNS disorders, including the areas of its current focus, rare hypersomnolence (specifically, narcolepsy) and complex neurodevelopmental disorders. NLS’s registered office and principal executive offices are located at The Circle6, 8058 Zurich, Switzerland. NLS’s telephone number in Switzerland is +41.44.512.2150 and its website address is https://nlspharma.com. The SEC also maintains an internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. NLS’s filings with the SEC are available to the public through the SEC’s website at www.sec.gov. The information contained on, or that can be